The therapeutic potential of cannabinoids for movement disorders.
Identifieur interne : 000016 ( PubMed/Corpus ); précédent : 000015; suivant : 000017The therapeutic potential of cannabinoids for movement disorders.
Auteurs : Benzi Kluger ; Piera Triolo ; Wallace Jones ; Joseph JankovicSource :
- Movement disorders : official journal of the Movement Disorder Society ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Cannabinoids, Neuroprotective Agents.
- drug therapy : Movement Disorders.
- metabolism : Basal Ganglia.
- pathology : Movement Disorders.
- Animals, Humans.
Abstract
There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.
DOI: 10.1002/mds.26142
PubMed: 25649017
Links to Exploration step
pubmed:25649017Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The therapeutic potential of cannabinoids for movement disorders.</title><author><name sortKey="Kluger, Benzi" sort="Kluger, Benzi" uniqKey="Kluger B" first="Benzi" last="Kluger">Benzi Kluger</name><affiliation><nlm:affiliation>Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Triolo, Piera" sort="Triolo, Piera" uniqKey="Triolo P" first="Piera" last="Triolo">Piera Triolo</name></author><author><name sortKey="Jones, Wallace" sort="Jones, Wallace" uniqKey="Jones W" first="Wallace" last="Jones">Wallace Jones</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25649017</idno><idno type="pmid">25649017</idno><idno type="doi">10.1002/mds.26142</idno><idno type="wicri:Area/PubMed/Corpus">000016</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The therapeutic potential of cannabinoids for movement disorders.</title><author><name sortKey="Kluger, Benzi" sort="Kluger, Benzi" uniqKey="Kluger B" first="Benzi" last="Kluger">Benzi Kluger</name><affiliation><nlm:affiliation>Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Triolo, Piera" sort="Triolo, Piera" uniqKey="Triolo P" first="Piera" last="Triolo">Piera Triolo</name></author><author><name sortKey="Jones, Wallace" sort="Jones, Wallace" uniqKey="Jones W" first="Wallace" last="Jones">Wallace Jones</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="e-ISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Basal Ganglia (metabolism)</term><term>Cannabinoids (therapeutic use)</term><term>Humans</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (pathology)</term><term>Neuroprotective Agents (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cannabinoids</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25649017</PMID><DateCreated><Year>2015</Year><Month>03</Month><Day>11</Day></DateCreated><DateCompleted><Year>2015</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>The therapeutic potential of cannabinoids for movement disorders.</ArticleTitle><Pagination><MedlinePgn>313-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26142</ELocationID><Abstract><AbstractText>There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.</AbstractText><CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kluger</LastName><ForeName>Benzi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triolo</LastName><ForeName>Piera</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Wallace</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K02 NS080885</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002186">Cannabinoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 2011 Aug;163(7):1495-506</RefSource><PMID Version="1">21323909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Saf. 2011 Sep;10(5):675-85</RefSource><PMID Version="1">21542664</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CNS Neurosci Ther. 2011 Dec;17(6):637-44</RefSource><PMID Version="1">20875047</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatry Res. 2011 Dec 30;190(2-3):382</RefSource><PMID Version="1">21664699</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Res. 2012 Mar;72(3):236-42</RefSource><PMID Version="1">22192465</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Alcohol Depend. 2012 Jun;123 Suppl 1:S99-S104</RefSource><PMID Version="1">22572210</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):21-9</RefSource><PMID Version="1">22265889</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Chem Neurosci. 2012 May 16;3(5):400-6</RefSource><PMID Version="1">22860209</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47</RefSource><PMID Version="1">22236282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychopharmacol. 1988 Dec;8(6):444-5</RefSource><PMID Version="1">3235704</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 1989 Feb;236(2):120-2</RefSource><PMID Version="1">2709054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1989 Dec;86(23):9584-7</RefSource><PMID Version="1">2556719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1990 May;53(5):436</RefSource><PMID Version="1">2351975</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Biochem Behav. 1991 Nov;40(3):701-8</RefSource><PMID Version="1">1839644</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1993 Nov;61(5):1705-12</RefSource><PMID Version="1">7901331</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Gen Psychiatry. 1995 Mar;52(3):219-29</RefSource><PMID Version="1">7872850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 1994 Nov 3;264(3):371-7</RefSource><PMID Version="1">7698178</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Neurol. 1997;38(1):44-8</RefSource><PMID Version="1">9252798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1998 Jun 5;248(3):171-4</RefSource><PMID Version="1">9654336</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1998 Nov;13(6):871-6</RefSource><PMID Version="1">9827609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Psychiatr Scand. 1998 Dec;98(6):502-6</RefSource><PMID Version="1">9879795</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 1998 Dec;21(12):521-8</RefSource><PMID Version="1">9881850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1999 Mar;156(3):495</RefSource><PMID Version="1">10080574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 2004 Oct 25;15(15):2375-9</RefSource><PMID Version="1">15640759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2005 Jan;20(1):113-5</RefSource><PMID Version="1">15390041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2009 Jun;29(11):2177-86</RefSource><PMID Version="1">19490092</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2009;(4):CD006565</RefSource><PMID Version="1">19821373</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 Nov;132(Pt 11):3152-64</RefSource><PMID Version="1">19805493</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2012 Oct 4;76(1):70-81</RefSource><PMID Version="1">23040807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Subst Abus. 2013;34(1):70-2</RefSource><PMID Version="1">23327506</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacotherapy. 2013 Feb;33(2):195-209</RefSource><PMID Version="1">23386598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Neurol. 2013;27(1):119-24</RefSource><PMID Version="1">23187140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1999 Nov;14(6):1038-40</RefSource><PMID Version="1">10584686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2000 Mar 2;404(6773):84-7</RefSource><PMID Version="1">10716447</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Life Sci. 2000;66(6):485-94</RefSource><PMID Version="1">10794065</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2000;97(3):505-19</RefSource><PMID Version="1">10828533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2000 Jul;14(10):1432-8</RefSource><PMID Version="1">10877836</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Psychiatry. 2001 Feb;178:107-15</RefSource><PMID Version="1">11157423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 2006 Fall;18(4):553-4</RefSource><PMID Version="1">17135385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2007 Feb 23;1134(1):162-70</RefSource><PMID Version="1">17196181</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2007 Feb 8;445(7128):643-7</RefSource><PMID Version="1">17287809</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2007 Jul 17;69(3):306-9</RefSource><PMID Version="1">17636069</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2007 Aug;26(4):843-51</RefSource><PMID Version="1">17672854</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chem Biodivers. 2007 Aug;4(8):1770-804</RefSource><PMID Version="1">17712819</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2007 Oct;323(1):318-26</RefSource><PMID Version="1">17630359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Neurobiol. 2007 Aug;36(1):82-91</RefSource><PMID Version="1">17952653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 2007 Nov;152(5):576-82</RefSource><PMID Version="1">17704824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2007 Nov;208(1):110-9</RefSource><PMID Version="1">17900568</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2008 Jan 2;151(1):104-10</RefSource><PMID Version="1">18068305</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Recent Pat CNS Drug Discov. 2007 Jun;2(2):131-9</RefSource><PMID Version="1">18221224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Neuropsychopharmacol. 2008 May;18(5):383-9</RefSource><PMID Version="1">18222654</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 2008 Jun 13;438(1):10-3</RefSource><PMID Version="1">18457923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Res. 2008 Aug;61(4):404-11</RefSource><PMID Version="1">18538428</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Thorac Oncol. 2008 Dec;3(12):1398-403</RefSource><PMID Version="1">19057263</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Pharmacol Sci. 2009 Mar;30(3):156-63</RefSource><PMID Version="1">19233486</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44</RefSource><PMID Version="1">19285266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Res. 2009 Aug;60(2):77-84</RefSource><PMID Version="1">19559360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Glia. 2009 Aug 15;57(11):1154-67</RefSource><PMID Version="1">19115380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Brain Res. 2009 Nov 5;203(2):304-7</RefSource><PMID Version="1">19414037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vitam Horm. 2009;81:389-419</RefSource><PMID Version="1">19647120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Psychopharmacol. 2009 Nov;23(8):979-83</RefSource><PMID Version="1">18801821</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CNS Neurol Disord Drug Targets. 2009 Dec;8(6):440-50</RefSource><PMID Version="1">19839933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Nov 15;24(15):2254-9</RefSource><PMID Version="1">19845035</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Neurosci. 2010;11:44</RefSource><PMID Version="1">20346144</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurol Res. 2010 Jun;32(5):451-9</RefSource><PMID Version="1">20307378</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychopharmacol. 2010 Apr;30(2):190-2</RefSource><PMID Version="1">20520294</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 2010 Jun;160(3):747-61</RefSource><PMID Version="1">20590577</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2010 Sep 29;170(1):324-36</RefSource><PMID Version="1">20600638</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2010 Sep;51(9):1413-7</RefSource><PMID Version="1">20720046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2010 Dec 2;1363:40-8</RefSource><PMID Version="1">20888328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2011 Feb-Mar;60(2-3):418-22</RefSource><PMID Version="1">21029743</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2011 Feb;336(2):423-30</RefSource><PMID Version="1">20966038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci Res. 2011 Sep;89(9):1509-18</RefSource><PMID Version="1">21674569</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jun 5;370(23):2219-27</RefSource><PMID Version="1">24897085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Epilepsia. 2014 Jun;55(6):791-802</RefSource><PMID Version="1">24854329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 2014 Aug;171(16):3908-17</RefSource><PMID Version="1">24762058</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3149-56</RefSource><PMID Version="1">25024177</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2014 Aug;29(9):1097-9</RefSource><PMID Version="1">24976412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharm Ther. 2014 Oct;39(5):564-6</RefSource><PMID Version="1">24845114</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Psychopharmacol. 2014 Nov;28(11):1088-98</RefSource><PMID Version="1">25237116</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Drug Policy. 2015 Feb;26(2):135-42</RefSource><PMID Version="1">25168081</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Struct Funct. 2015 Sep;220(5):2721-38</RefSource><PMID Version="1">24972960</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 2001 Jul 20;12(10):2125-9</RefSource><PMID Version="1">11447320</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 2001 Jun;156(1):79-85</RefSource><PMID Version="1">11465637</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Dec 11;57(11):2108-11</RefSource><PMID Version="1">11739835</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Jan;17(1):145-9</RefSource><PMID Version="1">11835452</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 2002 Apr;44(1):23-35</RefSource><PMID Version="1">11842443</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2001 Dec;14(11):1827-32</RefSource><PMID Version="1">11860478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2002 Mar 8;929(2):236-42</RefSource><PMID Version="1">11864629</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacopsychiatry. 2002 Mar;35(2):57-61</RefSource><PMID Version="1">11951146</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Rev. 2002 Jun;54(2):161-202</RefSource><PMID Version="1">12037135</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2002 Aug 15;22(16):6900-7</RefSource><PMID Version="1">12177188</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pain Symptom Manage. 2002 Jul;24(1):4-6</RefSource><PMID Version="1">12183086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 2002 Nov 15;454(2-3):145-51</RefSource><PMID Version="1">12421641</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Nov;17(6):1180-7</RefSource><PMID Version="1">12465055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Feb;18(2):138-49</RefSource><PMID Version="1">12539206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2003 Feb;28(2):384-8</RefSource><PMID Version="1">12589392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2003 Mar;84(5):1097-109</RefSource><PMID Version="1">12603833</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Psychiatry. 2003 Apr;64(4):459-65</RefSource><PMID Version="1">12716250</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2003 May;85(4):1018-25</RefSource><PMID Version="1">12716433</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 2003 May 6;14(6):813-6</RefSource><PMID Version="1">12858038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2005 Apr;18(3):591-601</RefSource><PMID Version="1">15755685</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics J. 2005;5(2):135-41</RefSource><PMID Version="1">15668727</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107</RefSource><PMID Version="1">15837565</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2005 May;57(5):777-9</RefSource><PMID Version="1">15852389</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2005 May;5(5):400-11</RefSource><PMID Version="1">15864274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2005 Jul;19(9):1140-2</RefSource><PMID Version="1">15894565</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2005 Jul 19;1050(1-2):210-6</RefSource><PMID Version="1">15975564</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2005 Oct 14;310(5746):329-32</RefSource><PMID Version="1">16224028</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Neuropsychopharmacol. 2006 Jan;16(1):7-18</RefSource><PMID Version="1">16006105</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2006 Feb 16;1073-1074:209-19</RefSource><PMID Version="1">16412990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Handb Exp Pharmacol. 2005;(168):445-77</RefSource><PMID Version="1">16596784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2006 Aug 30;1107(1):199-205</RefSource><PMID Version="1">16822488</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2006 Oct;51(5):1004-12</RefSource><PMID Version="1">16895732</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS J. 2013 May;280(9):1918-43</RefSource><PMID Version="1">23551849</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2013 Jul;53(7):680-90</RefSource><PMID Version="1">23754596</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Pharmacol. 2013 Dec;24(8):640-52</RefSource><PMID Version="1">24196024</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2014 Jan;13(1):100-12</RefSource><PMID Version="1">24331796</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurotherapeutics. 2014 Jan;11(1):117-27</RefSource><PMID Version="1">24282121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Alcohol Depend. 2014 Mar 1;136:158-61</RefSource><PMID Version="1">24440049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4</RefSource><PMID Version="1">24614667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2014 May;85(5):573-5</RefSource><PMID Version="1">24259592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2014 Apr 29;82(17):1556-63</RefSource><PMID Version="1">24778283</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2014 May;311(20):2053-4</RefSource><PMID Version="1">24828256</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Toxicol. 2003 Aug;93(2):66-70</RefSource><PMID Version="1">12899667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2003 Nov 8;362(9395):1517-26</RefSource><PMID Version="1">14615106</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2003 Nov;110(11):1279-88</RefSource><PMID Version="1">14628192</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2004 May 8;1007(1-2):152-9</RefSource><PMID Version="1">15064146</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2004 Apr 13;62(7):1105-9</RefSource><PMID Version="1">15079008</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2004 Jun;29(6):1134-42</RefSource><PMID Version="1">15010694</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2004 May-Jun;27(3):108-10</RefSource><PMID Version="1">15190231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 Jun;19(6):708-9</RefSource><PMID Version="1">15197714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 Sep;19(9):1102-6</RefSource><PMID Version="1">15372606</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2004 Oct 12;63(7):1245-50</RefSource><PMID Version="1">15477546</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Biochem Behav. 1981 Nov;15(5):779-83</RefSource><PMID Version="1">6273940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1983 Jun;13(6):669-71</RefSource><PMID Version="1">6309074</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Neurosci. 1986 Nov;30(4):277-82</RefSource><PMID Version="1">3793381</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002186">Cannabinoids</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS649683 [Available on 03/01/16]</OtherID><OtherID Source="NLM">PMC4357541 [Available on 03/01/16]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Huntington's disease</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">cannabis</Keyword><Keyword MajorTopicYN="N">movement disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2015</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25649017</ArticleId><ArticleId IdType="doi">10.1002/mds.26142</ArticleId><ArticleId IdType="pmc">PMC4357541</ArticleId><ArticleId IdType="mid">NIHMS649683</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25649017
|texte= The therapeutic potential of cannabinoids for movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25649017" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |